Rare Conversations podcast: Regulatory fragmentation across countries
Your essential checklist for an effective regulatory submission
Bringing a new drug to market is a complex, [...]
10 common pharmacovigilance inspection findings and their implications
Pharmacovigilance (PV) plays a crucial role in assuring patient [...]
Taking an inquirer-centric approach to rare disease medical information
By Marcelo Vaz, Vice President of Medical Services at [...]
The importance of incorporating decentralised clinical trials (DCTS) and patient centricity by design in rare disease studies
By Marcelo Vaz, Vice President of Medical Services at [...]
3 common UK MHRA marketing authorisation challenges (and how to solve them)
Biotech and pharmaceutical companies face numerous challenges when commercialising [...]